Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 4/20 | 0.82 |
| ▸ | JAK3 | P52333 | 4/20 | 0.82 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.82 |
| ▸ | CYP2C8 | P10632 | 3/20 | 0.82 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.82 |
| ▸ | JAK1 | P23458 | 3/20 | 0.82 |
| ▸ | TYK2 | P29597 | 3/20 | 0.82 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.82 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.82 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.82 |
| ▸ | AURKA | O14965 | 4/20 | 0.62 |
| ▸ | AURKB | Q96GD4 | 3/20 | 0.62 |
| ▸ | NTRK1 | P04629 | 8/20 | 0.55 |
| ▸ | GRK6 | P43250 | 1/20 | 0.52 |
| ▸ | NTRK3 | Q16288 | 4/20 | 0.50 |
| ▸ | NTRK2 | Q16620 | 4/20 | 0.50 |
| ▸ | SRC | P12931 | 1/20 | 0.47 |
| ▸ | EIF2AK2 | P19525 | 1/20 | 0.47 |
| ▸ | GSK3A | P49840 | 1/20 | 0.47 |
| ▸ | GSK3B | P49841 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL255907 | 1.00 | JAK2 (0.82) | JAK2JAK3CYP3A4CYP2C8CYP2C9 | |
| SCHEMBL174394 | 1.00 | JAK2 (0.82) | JAK2JAK3CYP3A4CYP2C8CYP2C9 | |
| SCHEMBL720853 | 1.00 | JAK2 (0.82) | JAK2JAK3CYP3A4CYP2C8CYP2C9 | |
| SCHEMBL187202 | 0.94 | JAK2 (0.79) | JAK2JAK3CYP3A4CYP2C8CYP2C9 | |
| SCHEMBL187203 | 0.94 | JAK2 (0.79) | JAK2JAK3CYP3A4CYP2C8CYP2C9 | |
| SCHEMBL255143 | 0.94 | JAK2 (0.79) | JAK2JAK3CYP3A4CYP2C8CYP2C9 | |
| SCHEMBL173738 | 0.94 | JAK2 (0.79) | JAK2JAK3CYP3A4CYP2C8CYP2C9 | |
| SCHEMBL188199 | 0.93 | JAK2 (0.78) | JAK2JAK3CYP3A4CYP2C8CYP2C9 | |
| SCHEMBL163301 | 0.93 | JAK2 (0.78) | JAK2JAK3CYP3A4CYP2C8CYP2C9 | |
| SCHEMBL174670 | 0.92 | JAK2 (0.76) | JAK2JAK3CYP3A4CYP2C8CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9308207-B2 | JAK kinase modulating compounds and methods of use thereof | AMBIT BIOSCIENCES CORP. (US) | 2016-04-12 | — | — | US | disclosed |
| US-20150150874-A1 | JAK KINASE MODULATING COMPOUNDS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORP. (US) | 2015-06-04 | — | — | US | disclosed |
| US-8927711-B2 | JAK kinase modulating compounds and methods of use thereof | AMBIT BIOSCIENCES CORP. (US) | 2015-01-06 | — | — | US | disclosed |
| EP-2401267-B1 | JAK KINASE MODULATING QUINAZOLINE DERIVATIVES AND THEIR USE IN METHODS | AMBIT BIOSCIENCES CORP (US) | 2014-01-15 | — | — | EP | disclosed |
| US-20130245014-A1 | JAK KINASE MODULATING COMPOUNDS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORP. (US) | 2013-09-19 | — | — | US | disclosed |
| US-8349851-B2 | JAK kinase modulating compounds and methods of use thereof | AMBIT BIOSCIENCES CORP. (US) | 2013-01-08 | — | — | US | disclosed |
| US-20120053176-A1 | ADENOSINE A3 RECEPTOR MODULATING COMPOUNDS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORP. (US) | 2012-03-01 | — | — | US | disclosed |
| EP-2401267-A1 | JAK KINASE MODULATING QUINAZOLINE DERIVATIVES AND METHODS OF USE THEREOF | Ambit Biosciences Corporation (US) | 2012-01-04 | — | — | EP | disclosed |
| US-20100317659-A1 | JAK KINASE MODULATING COMPOUNDS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORP. | 2010-12-16 | — | — | US | disclosed |
| WO-2010099379-A1 | JAK KINASE MODULATING QUINAZOLINE DERIVATIVES AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORPORATION (US) | 2010-09-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150150874-A1 | JAK KINASE MODULATING COMPOUNDS AND METHODS OF USE THEREOF | JAK2, JAK3, JAK1 | JAK2 1/4885JAK3 2/4885CYP3A4 3115/4885 |
| US-20130245014-A1 | JAK KINASE MODULATING COMPOUNDS AND METHODS OF USE THEREOF | JAK2, JAK3, JAK1 | JAK2 1/4885JAK3 2/4885CYP3A4 3115/4885 |
| US-20100317659-A1 | JAK KINASE MODULATING COMPOUNDS AND METHODS OF USE THEREOF | JAK2, JAK3, JAK1 | JAK2 1/4885JAK3 2/4885CYP3A4 3115/4885 |
| US-20120053176-A1 | ADENOSINE A3 RECEPTOR MODULATING COMPOUNDS AND METHODS OF USE THEREOF | ADORA2A, ADORA3, ADORA1 | JAK2 3914/4885JAK3 3339/4885CYP3A4 2890/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.